Aescap Venture
VC Fund
Amsterdam, The Netherlands
Aescap Venture is an Amsterdam-based investment company that pursues investments in biotech companies in Europe and the U.S.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 40%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Aescap Venture invests in
BiotechnologyPharmaceuticalHealth DiagnosticsBiopharmaChemical
Stages Aescap Venture invests in
Series BSeries ASeries CPost-IPO EquityVenture - Series Unknown
Countries Aescap Venture invests in
SwitzerlandUnited KingdomThe NetherlandsAustriaBelgium
Round sizes
Series A $1.5M–$20MSeries B $5.2M–$33M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.5M–$20M
- Series B
- $5.2M–$33M
Investment Focus
Industry
- Biotechnology 10 (50%)
- Pharmaceutical 5 (25%)
- Health Diagnostics 4 (20%)
- Biopharma 3 (15%)
- Chemical 2 (10%)
Stage
- Series B 4 (20%)
- Series A 3 (15%)
- Series C 2 (10%)
- Post-IPO Equity 2 (10%)
- Venture - Series Unknown 2 (10%)
Country
- Switzerland 2 (10%)
- United Kingdom 2 (10%)
- The Netherlands 2 (10%)
- Austria 1 (5%)
- Belgium 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michiel de Haan
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 3 | Find email | |
Wolfgang Noeldeke
Financial officer
|
Financial officer | Total investments: 0 | Find email | |
Patrick Krol
managing partner
|
managing partner | Total investments: 1 | Find email | |
|
Rainer Christine
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| F-Star Therapeutics is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab:tm: antibody fragments, and bispecificantibodies, by modifying the constant region of an antibody. In particular, F-star’s Modular Antibody Technology:tm: enables rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology, F-star generates bispecific antibodies (mAb2:tm:) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates. Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture, Novo Ventures and TVM Capital; as well as from renowned strategic corporate investors: Merck Serono Ventures, MP Healthcare Venture Management and SR One. In 2013, F-star established an asset-centric vehicle structure through the formation of F-star Alpha Ltd., which included out-licensing of FS102 from F-star to F-star Alpha Ltd. In October 2014 Bristol-Myers Squibb obtained an exclusive option to buy F-star Alpha. In addition the company has alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. In 2011, F-star was selected by FierceBiotech as one of the Fierce 15 winners. F-star currently employs over 35 people at its research site in Cambridge, UK. | $15M / Post-IPO Equity / Nov 20, 2020 | ||
| Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA. | $87.8M / Post-IPO Equity / Nov 24, 2017 | ||
| Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA. | $94.2M / Venture - Series Unknown / Nov 16, 2017 | ||
| Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA. | $14.8M / Venture - Series Unknown / Mar 08, 2017 | ||
| i-Optics pioneers smart and superior eye diagnosis solutions that are affordable, fast and user-friendly for care providers worldwide to serve their patients best. Its innovations include:• Cassini – A first-of-its-kind Corneal Shape Analyzer based on Color LED Technology. Cassini measures the true axis and magnitude of corneal astigmatism and isessential for premium IOL planning. Put an end to unexpected refractive outcomes for your astigmatic cataract patients with Cassini from i-Optics.• EasyScan – A breakthrough, zero-dilation retinal imaging system that uses SLO technology to diagnose retinal diseases including diabetic retinopathy, age-related macular degeneration (AMD) and glaucoma. | $15.1M / Venture - Series Unknown / May 22, 2015 | ||
| Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA. | $24M / Series B / Jan 09, 2015 | ||
| Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations. | $42.1M / Series G / May 22, 2014 | ||
| Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA. | $20M / Series A / Sep 07, 2011 | ||
| Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations. | $48.2M / Jun 09, 2011 | ||
| Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexeddetection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland. | $32.9M / Series B / Apr 08, 2010 | ||
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
48,627 investors
Biotech Investors
24,131 investors
Biotechnology Investors
21,397 investors
Health Care VC Funds
36,465 investors
Biotech VC Funds
20,850 investors
Biotechnology VC Funds
18,763 investors
Health Care Angel Investors
12,162 investors
Biotech Angel Investors
3,281 investors
Biotechnology Angel Investors
2,634 investors
FAQ
What does Aescap Venture invest in?
Aescap Venture invests primarily in Biotechnology, Pharmaceutical and Health Diagnostics startups, most often at Series B and Series A stage. Most of the 20 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Aescap Venture's check size?
Aescap Venture typically joins rounds of $1.5M–$20M at Series A and $5.2M–$33M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Aescap Venture participates in.
How do I contact Aescap Venture?
Public channels for Aescap Venture include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Aescap Venture?
The team at Aescap Venture includes Michiel de Haan (Founder and Managing Partner), Wolfgang Noeldeke (Financial officer) and Patrick Krol (managing partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
